Synklino strives to provide rapid relief as well as to improve long-term survival for transplant recipients by providing fast and safe eradication of cytomegalovirus (CMV) infections. Our drug candidate SYNx efficiently eliminates both lytic as well as latently infected cells, and thereby potently inhibits viral replication and eradicates the virus - simply taking CMV out of the equation for the transplant recipient. SYNx highly potently, efficiently and selectively eliminates CMV infected cells through a proven mechanism, allowing for both stand-alone and combination therapy.

Advancing Innovation in the Life Science and health care Industries, by facilitating the convergence of industry challenges and market needs with university research.

Leading the Section for Virology. Line/budget/strategy manager for 50+ staff, incl. 25VIP.

Strategy development and stakeholder management

INAGEN Create Novel Biopharmaceuticals for Better Antiviral Treatments. Co-founded INAGEN in 2007, build a flourishing team of outstanding scientists and directed the company’s research and development.

Drug discovery

Group leader of Cell Biology and Virology at the Department of Micro and Nanotechnology.

Group leader, virology, cell biology and molecular pharmacology

Molecular and experimental virology

Molecular pharmacology of GPCRs